<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21875">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140112</url>
  </required_header>
  <id_info>
    <org_study_id>CNDO 201-101</org_study_id>
    <nct_id>NCT02140112</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coronado Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coronado Biosciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, 2-arm, placebo-controlled crossover study in pediatric
      patients with autism spectrum disorder with all patients receiving 16-weeks of TSO treatment
      and 16 weeks of placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Aberrant Behavior Checklist - Irritability (ABC-I) at 16 weeks</measure>
    <time_frame>36 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Trichuris suis ova</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 8 doses every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trichuris suis ova</intervention_name>
    <arm_group_label>Trichuris suis ova</arm_group_label>
    <other_name>TSO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, 5 to 17 years of age

          -  Patients must fulfill DSM-V diagnostic criteria for autism spectrum disorder
             ascertained at screening, using a clinical review confirmed by the Autism Diagnosis
             Observation Schedule - Second edition (ADOS-2)

          -  Written informed consent from parent(s) or legal guardian(s) with sufficient
             intellectual capacity to understand the study and support patients' adherence to the
             study procedures must be obtained for patients who are not emancipated.  In
             accordance with Institutional Review Board (IRB) requirements, the patient will
             complete an informed assent when developmentally appropriate, to participate in the
             study before conduct of any study-specific procedures.

          -  Patients are able and willing to swallow study medication suspension.

        Exclusion Criteria:

          -  Known diagnosis of syndromal form of Autism (e.g. Rett Syndrome, Childhood
             Disintegrative Disorder, Fragile X Syndrome, etc.)

          -  Patients who cannot discontinue anti-psychotic medication

          -  Patients with current active seizure disorder or who have had a seizure within the
             last 6 months prior to screening

          -  Female patient who is pregnant or breastfeeding or wishing to become pregnant during
             study participation or unwilling to use birth control.

          -  Patients who have received helminthic treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Ryan</last_name>
    <phone>781-652-4514</phone>
    <email>mryan@coronadobio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Wheeler</last_name>
    <phone>781-652-4509</phone>
    <email>awheeler@coronadobio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southwest Autism Research &amp; Resource Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharman Ober-Reynolds</last_name>
      <phone>602-218-8225</phone>
      <email>SOberReynolds@autismcenter.org</email>
    </contact>
    <investigator>
      <last_name>Raun Melmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elissa Molloy-Plaza</last_name>
      <phone>281-893-4111</phone>
      <email>ropa7@earthlink.net</email>
    </contact>
    <contact_backup>
      <last_name>Julie Brekke</last_name>
      <phone>281 893-4111</phone>
      <email>ropa20@redoakpsychiatry.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Ginsberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>May 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T. suis ova</keyword>
  <keyword>Trichuris suis ova</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>ASD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
